<DOC>
	<DOC>NCT01423318</DOC>
	<brief_summary>This randomized, double-blind, placebo-controlled, parallel-group study will evaluate the safety and pharmacokinetics of subcutaneous lebrikizumab in healthy Japanese volunteers. Healthy Japanese and Caucasian volunteers will be randomized to receive a single subcutaneous dose of either lebrikizumab or placebo.</brief_summary>
	<brief_title>A Study of Lebrikizumab in Healthy Japanese and Caucasian Volunteers</brief_title>
	<detailed_description />
	<mesh_term>Antibodies, Monoclonal</mesh_term>
	<criteria>Adult healthy males and females, 18 to 55 years of age inclusive Caucasian, Japanese, or nonJapanese subjects. Caucasian or nonJapanese subjects will have no parents or grandparents of Japanese descent; Japanese subjects must be first, second or third generation Body weight between 45 and 105 kg, inclusive In good health, determined by no clinically significant findings from medical history, 12lead ECG, vital signs, and laboratory evaluations Fertile males and women of childbearing potential must use appropriate form of contraception from screening until 60 days after study completion Negative for hepatitis B, hepatitis C, and HIV infection Negative for selected drugs of abuse at screening (not including alcohol) and at checkin (including alcohol) Pregnant and lactating women History of clinically significant drug allergy and/or a known hypersensitivity to the study drug or formulation components History of helminthic infection or travel within the past 3 months to areas of high risk for parasitic exposure Use of prescription drugs including inhaled, oral, or parenteral corticosteroids and/or beta agonists, within 7 days prior to dosing or during the study Use of tobacco or nicotinecontaining products from 7 days prior to checkin, resulting in urinary cotinine &gt;500 ng/mL. Minimal/intermittent smoking will be permitted during the study Participation in any other investigational drug trial in which receipt of an investigational study drug occurred within 30 days or 5 halflives, whichever is longer, prior to checkin (Day 1) History of significant, chronic, or recurrent infections requiring treatment</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>